Hydroxyurea improves cardiac abnormalities in young patients with sickle cell anemia: Study

Prolonged hydroxyurea therapy may reverse cardiac complications in children and young adults with sickle cell anemia.

USA: Cardiac abnormalities such as left ventricular hypertrophy, dilation, and pulmonary hypertension are common in children and young adults with sickle cell anemia. A recent study in the journal Blood Advances has provided evidence that prolonged hydroxyurea therapy in such patients may lead to reverse cardiac remodeling and improve these cardiac abnormalities. 

Hydroxyurea is a disease-modifying therapy for sickle cell anemia that has been used for several decades. However, there is a lack of longitudinal assessment of echocardiographic abnormalities in children and young adults having sickle cell anemia. To fill this knowledge gap, Arushi Dhar, Cohen Children's Medical Center, New Hyde Park, New York, United States, and colleagues aimed to determine the prevalence of echocardiographic abnormalities in children and young adults with sickle cell anemia and to examine the effects of hydroxyurea on reverse cardiac remodeling. 

Working towards their aim, the researchers reviewed the records of patients with sickle cell anemia who underwent routine cardiac screening at Cohen Children's Medical Center between 2010 and 2017. This was followed by a retrospective longitudinal analysis of echocardiograms performed on patients receiving treatment with hydroxyurea. Data on a total of 100 patients with sickle cell anemia were analyzed; 60 (60%) were on hydroxyurea. 

Based on the results, the authors concluded, "timely initiation of treatment with hydroxyurea may lead to reverse cardiac remodeling and improvement in these cardiac abnormalities. Future studies should attempt to follow this patient cohort for a longer duration."

Reference:

The study titled, "Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy," is published in the journal Blood Advances.

DOI: https://doi.org/10.1182/bloodadvances.2021005076